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Cold visceral perfusion improves early survival in
patients with acute renal failure after
thoracoabdominal aortic aneurysm repair
Heitham T. Hassoun, MD, Charles C. Miller III, PhD, Tam T. T. Huynh, MD, Anthony L. Estrera,
MD, Jesse J. Smith, BS, and Hazim J. Safi, MD, Houston, Tex
Introduction: Despite advances in organ protection during thoracoabdominal aortic aneurysm (TAAA) repair, acute renal
failure (ARF) remains a significant clinical problem, associated with increased morbidity and mortality. We studied
outcome of ARF after TAAA repair in patients who underwent either warm or cold visceral perfusion.
Method: Between 1991 and 2001 657 TAAA repairs were performed, of which 359 (55%) had either warm or cold visceral
perfusion. Twelve patients with renal failure who had undergone preoperative dialysis were excluded from the study. Of
the remaining 347 patients, ARF developed in 81 (23%) after TAAA repair. Forty-four (54%) of the 81 patients with ARF
received cold visceral perfusion, and 37 (46%) patients received warm visceral perfusion. ARF was defined as either an
increase of 1 mg/dL in serum creatinine (SCr) concentration per day for 2 consecutive days or dialysis requirement.
Patient records were reviewed through hospital discharge.
Results: Twenty six (32%) of the 81 patients in whom ARF developed died, 17 of 37 (46%) patients in the warm perfusion
group versus 9 of 44 (21%) patients in the cold perfusion group (P < .02). Median onset of ARF was on postoperative
day 1 in both groups. Twenty-six of 81 (32%) patients recovered renal function, 10 of 37 (27%) patients in the warm
perfusion group versus 16 of 44 (36%) patients in the cold perfusion group. Preoperative SCr concentration was
predictive of recovery of renal function (odds ratio, 4.5 per mg/dL increase; P < .03) in patients who received either
warm or cold visceral perfusion.
Conclusions: ARF after TAAA repair remains a significant clinical problem. Recovery of renal function occurred in
approximately one third of patients. Preoperative SCr concentration was the only significant determinant of recovered
renal function. While cold visceral perfusion did not alter renal recovery, it significantly reduced hospital mortality. (J
Vasc Surg 2004;39:506-12.)
Despite advances in organ protection during thoraco-
abdominal aortic aneurysm (TAAA) repair, postoperative
acute renal failure (ARF) remains a significant clinical prob-
lem. The incidence of ARF after TAAA repair is between 4%
and 40%, and is associated with increased morbidity and
mortality.1-7 Several risk factors have been identified, in-
cluding advanced age, male sex, history of stroke, blood
transfusion requirement, preoperative renal dysfunction,
and visceral ischemia.8-10 We have adopted several surgical
adjuncts for renal protection, including distal aortic perfu-
sion and direct perfusion of the visceral artery ostia (celiac,
superior mesenteric, and renal arteries) during reimplanta-
tion of the visceral segment of aorta. However, using
multivariate analysis we previously identified warm visceral
perfusion as a risk factor for ARF.11
Subsequently we have adopted the use of visceral per-
fusion with cold blood for visceral organ and kidney pro-
tection. While therapeutic hypothermia has been used for
organ protection against ischemia/reperfusion (I/R) in-
jury in both laboratory animals and human beings, the
effect of visceral cooling on postoperative ARF after TAAA
repair remains unknown. Moreover, little is known about
recovery of renal function in this patient population. The
purpose of this study was to evaluate outcome of ARF after
TAAA repair in patients who underwent either warm or
cold blood visceral perfusion.
METHOD AND MATERIAL
Between 1991 and 2001 we performed 657 TAAA
repairs, in which 359 (55%) patients underwent either
warm blood visceral perfusion (171 patients; 47%) or cold
blood visceral perfusion (188 patients; 53%) Patients
treated before 1996 underwent warm visceral perfusion. In
early 1996 we began to use cold visceral perfusion in an
attempt to provide improved renal protection. Patients
were therefore selected to undergo warm or cold perfusion,
not by individual characteristics but by the period in which
they had surgery. All data were collected prospectively and
entered into our standardized database for this historical
cohort study. Patient charts were followed up until death or
discharge from the hospital. Twelve patients undergoing
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dialysis preoperatively were excluded from the study. Of the
remaining 347 patients, 81 (23%) developed ARF after
TAAA repair, and form the basis for this study, 37 of 171
patients (22%) in the warm visceral perfusion group and 44
of 188 (23%) patients in the cold perfusion group. ARF was
defined as an increase in serum creatinine (Scr) concentra-
tion of 1 mg/dL per day for 2 consecutive days or dialysis
requirement. Recovery of renal function was defined as
cessation of renal replacement therapy or return of serum
creatinine concentration to baseline without dialysis before
hospital discharge.
Warm visceral perfusion was used in 37 (46%) patients,
compared with cold visceral perfusion in 44 (54%) patients.
Thirty-three (41%) patients were women, and 48 (59%)
patients were men; median age was 69 years (range, 28-82
years). Median preoperative Scr concentration was 1.2
mg/dL (range, 0.6-5.5 mg/dL). The extent of aneurysms
in both groups was similar (Fig 1).
The operative technique for repair of these aneurysms
has been described in detail.12 All patients underwent distal
aortic perfusion. The techniques used for both warm and
cold visceral perfusion are shown in Fig 2. For distal aortic
perfusion the left atrium or inferior pulmonary vein was
cannulated with a No. 26 Bard aortic cannula (L. R. Bard,
Haverhill, Mass) connected to a Biomedicus pump (Bio-
medicus, Minneapolis, Minn) with an in-line heat ex-
changer. The left femoral artery was exposed through a
longitudinal groin incision, and cannulated with a 16F to
20F cannula connected to the pump. Flow was dependent
on the proximal aortic pressure, which was kept at more
than 100 mm Hg. During reimplantation of the visceral
vessels, 9F or 12F Pruitt catheters were inserted into the
ostia of the celiac, superior mesenteric, and renal arteries,
and were perfused with either warm (37°C) or cold (4°C)
blood with a heat exchanger connected to the circuit. A
temperature probe was inserted into the left kidney. The
Fig 1. Classification of thoracoabdominal aortic aneurysms. Table at bottom shows extent distribution in patients who
received warm or cold visceral perfusion.
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renal temperature was maintained between 15°C and
20°C. The total visceral flow rates ranged from 300 to 450
mL/min.
Statistical analysis. Data were collected prospectively
and entered into a Microsoft Access database. Univariate
data were analyzed with contingency table methods for
renal function recovery and 30-day mortality end points.
Common odds ratios and test-based 95% confidence inter-
vals were computed, along with 2 P values. Multivariate
analyses for renal function recovery were computed with
multiple logistic regression. All analyses were performed
with SAS software (version 8.02; SAS Inc, Cary, NC).
RESULTS
The overall 30-day mortality rate for patients in whom
ARF developed after TAAA repair was 32% (26 of 81).
Hospital mortality in the cooled group was 27% (12 of 44),
versus 56% (19 of 34) in the warmed group (P  .02).
Univariate analysis of patient characteristics and resulting
30-day mortality are shown in Table I. Age, sex, preopera-
tive Scr concentration, aneurysm extent, aortic clamp time,
pump time, history of chronic obstructive pulmonary dis-
ease, hypertension, and previous renal insufficiency were
not predictive of higher mortality in patients in whom ARF
developed. However, mortality for patients who under-
went warm visceral perfusion (46%, 17 of 37) was signifi-
cantly greater than for patients who underwent cold visceral
perfusion (21%, 9 of 44; P  .02).
Median time to onset of ARF was postoperative day 1
in both cold and warm perfusion groups. Recovery of renal
function during the period of hospitalization occurred in
26 of 81 (32%) patients: 10 of 37 (27%) in the warm
perfusion group versus 16 of 44 (36%) patients in the cold
perfusion group (P  .37; Table II). Odds of recovery
decreased by 4.5-fold per gram per deciliter of SCr concen-
tration after both warm and cold visceral perfusion (P 
.03; Fig 3). No other variables were associated with renal
function recovery.
DISCUSSION
Acute renal failure is a common clinical problem that
affects 5% to 7% of all hospitalized patients and carries a 20%
to 70% mortality rate.13 Several pharmacologic interven-
tions, such as dopamine, loop diuretics, atrial natriuretic
peptides, nitric oxide inhibitors, and endothelin receptor
antagonists, have been studied for both prophylaxis and
treatment of ARF, without clinical success.14-17 In addi-
tion, despite advances in surgical technique, ARF after
TAAA repair remains a vexing problem, with incidence
ranging from 4% to 40%, depending on the series, and
associated increased morbidity and mortality.1-7
Perioperative renal I/R injury is believed to have a
central role in the pathogenesis of ARF after TAAA repair.
Intuitively, selective renal perfusion during reimplantation
of the visceral vessels should protect against renal ischemia
and subsequent ARF. However, in a previous study of
Fig 2. Warm and cold visceral perfusion techniques.
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mortality Odds ratio* 95% CI† P‡ P§
n % n %
All patients 81 100 26 32.1
Age (y)
28-63 20 25.0 9 45.0 0.97 0.93-1.02 .09 .23
64-69 23 27.5 5 21.7
70-74 19 23.8 9 47.4
75-82 19 23.7 3 15.8
Gender
Female 33 40.7 12 36.4 1.39 0.54-3.57 .50
Male 48 59.3 14 29.2 1
COPD
Yes 33 40.7 7 21.2 0.41 0.15-1.13 .09
No 48 59.3 19 39.6 1
Hypertension
Yes 68 84.0 24 35.3 3.00 0.61-14.66 .16
No 13 16.0 2 15.4 1
TAAA II
Yes 41 50.6 12 29.3 0.77 0.30-1.96 .59
No 40 49.4 14 35.0 1
Previous renal insufficiency
Yes 21 25.9 9 42.9 1.90 0.68-5.32 .22
No 60 74.1 17 28.3 1
SCr (mg/dL)
0.6-0.9 25 32.5 7 28.0 1.24 0.70-2.18 .72 .46
1.0-1.2 22 28.6 7 31.8
1.3-1.4 12 15.6 4 33.3
1.5-5.5 18 23.4 8 44.4
Perfusion type
Cool 44 54.3 9 20.5 0.30 0.11-0.80 .02
Warm 37 45.7 17 46.0 1
Clamp time (min)
19-42 20 25.0 8 40.0 1.00 0.98-1.02 .73 .84
43-60 21 26.3 5 23.8
61-74 19 23.7 6 31.6
75-149 20 25.0 7 35.0
Pump time (min)
20-50 20 25.0 9 45.0 0.99 0.98-1.01 .39 .76
51-72 22 27.4 6 27.3
73-89 19 23.8 4 21.1
90-171 19 23.8 7 36.8
Fresh-frozen plasma
0-6 21 26.9 4 19.1 1.03 0.98-1.08 .17 .48
7-12 28 35.9 10 35.7
13-20 12 15.4 4 33.3
21-44 17 21.8 7 41.1
Platelets
0-3 21 26.9 4 19.1 1.03 0.99-1.07 .09 .05
4-16 19 42.1 8 42.1
17-30 29 37.1 7 24.1
31-69 9 11.5 6 66.7
Packed red blood cells
(units)
0-4 22 28.2 6 27.3 1.11 1.02-1.20 .02 .32
5-8 25 32.1 7 28.0
9-10 13 16.7 3 23.1
11-40 18 23.1 9 50.0
Variables that do not sum to 81 have 81-N missing data values.
COPD, Chronic obstructive pulmonary disease; TAAA, thoracoabdominal aortic aneurysm; SCr, serum creatinine concentration.
*For dichotomous variables, odds ratio represents a test against a reference category with referent odds ratio equal to 1. For continuous data, odds ratio refers
to increase in odds associated with a one-unit increase in variable value. Although continuous data are presented in quartiles, odds ratios are against the
continuous variable.
†95% CI, 95% confidence interval. This reflects units against which its companion odds ratio is computed. Confidence intervals are test-based.
‡Pearson 2 analysis.
§Univariate logistic regression likelihood ratio.
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Odds ratio* 95% CI† P‡ P§n % n %
All patients 81 100 26 32.1
Age (y)
28-63 20 25.0 5 25.0 1.04 0.99-1.10 .04 .15
64-69 23 27.5 9 39.1
70-74 19 23.8 2 10.5
75-82 19 23.7 10 52.6
Gender
Female 33 40.7 13 39.3 1.75 0.68-4.50 .25
Male 48 59.3 13 27.1 1
COPD
Yes 33 40.7 11 33.3 1.10 0.43-2.84 .85
No 48 59.3 15 31.3 1
Hypertension
Yes 68 84.0 23 33.8 1.70 0.43-6.80 .45
No 13 16.0 3 23.1 1
TAAA II
Yes 41 50.6 13 31.7 0.96 0.38-2.45 .94
No 40 49.4 13 32.5 1
Previous renal insufficiency
Yes 21 25.9 5 23.8 0.58 0.19-1.80 .35
No 60 74.1 21 35.0 1
SCr
0.6-0.9 25 32.5 12 48.0 0.22 0.06-0.86 .17 .03
1.0-1.2 22 28.6 7 31.8
1.3-1.4 12 15.6 3 25.0
1.5-5.5 18 23.4 3 16.7
Perfusion type
Cool 44 54.3 16 36.4 1.54 0.59-3.99 .37
Warm 37 45.7 10 27.0 1
Clamp time (min)
19-42 20 25.0 9 45.0 0.97 0.95-0.99 .03 .01
43-60 21 26.3 9 42.9
61-74 19 23.7 7 36.8
75-149 20 25.0 1 5.0
Pump time (min)
20-50 20 25.0 7 35.0 0.99 0.97-1.01 .33 .24
51-72 22 27.4 8 36.4
73-89 19 23.8 8 42.1
90-171 19 23.8 3 15.8
Fresh-frozen plasma
0-6 21 26.9 6 28.5 1.02 0.98-1.07 .36 .72
7-12 28 35.9 8 27.3
13-20 12 15.4 5 41.7
21-44 17 21.8 7 41.1
Platelets
0-3 21 26.9 6 28.5 1.00 0.97-1.04 .83 .42
4-16 19 24.4 5 26.3
17-30 29 37.2 13 44.8
31-69 9 11.5 2 22.2
Packed red blood cells (units)
0-4 22 28.2 5 22.7 0.98 0.91-1.05 .51 .49
5-8 25 32.1 11 44.0
9-10 13 16.7 4 30.8
11-40 18 23.1 6 33.3
Variables that do not sum to 81 have 81-N missing data values.
COPD, Chronic obstructive pulmonary disease; TAAA, thoracoabdominal aortic aneurysm; SCr, serum creatinine concentration.
*For dichotomous variables, odds ratio represents a test against a reference category with referent odds ratio equal to 1. For continuous data, odds ratio refers
to increase in odds associated with a one-unit increase in variable value. Although continuous data are presented in quartiles, odds ratios are against the
continuous variable.
†95% CI, 95% confidence interval. This reflects units against which its companion odds ratio is computed. Confidence intervals are test-based.
‡Pearson 2 analysis.
§Univariate logistic regression likelihood ratio.
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patients who underwent TAAA repair we found an in-
creased risk for ARF with the use of warm blood visceral
perfusion.11 While the mechanisms for increased risk for
ARF with warm visceral perfusion remain unclear, we have
subsequently adopted the use of visceral cooling to protect
against organ ischemia. In this study we demonstrate that
the use of cold visceral perfusion in 188 TAAA repairs had
no effect on the incidence of postoperative ARF or renal
recovery when compared with 171 TAAA repairs per-
formed with warm visceral perfusion. However, cold vis-
ceral perfusion significantly reduced hospital mortality in
patients with ARF when compared with warm visceral
perfusion.
Since the 1950s therapeutic hypothermia has been used
extensively, predominately during cardiac surgery, for pro-
tection against I/R injury. The mechanisms of hypother-
mic protection during I/R are multifactorial, and as yet are
not clearly defined. Several mechanisms have been pro-
posed, including reduction in oxygen demand and con-
sumption, oxidant injury, leukotriene production, interleu-
kin-1 production, and neutrophil accumulation.18 More
recently studies have focused on the molecular mechanisms
of hypothermic protection, including changes in transcrip-
tion factor activation and oxidative stress protein expression
during I/R.19 While local hypothermia protects against
renal I/R injury in laboratory animals, its clinical efficacy is
unknown.20,21 In a large retrospective series no significant
reduction in postoperative ARF with renal perfusion with
cold Ringer lactate solution during TAAA repair was iden-
tified.9 However, a recent prospective randomized study
that included 30 patients undergoing Crawford type II
TAAA repair demonstrated significant reduction in acute
renal dysfunction with the use of cold crystalloid perfusion
compared with warm blood perfusion.22 While this study is
limited by its small size and because the cold crystalloid
group also received mannitol and steroid agents, it demon-
strates the potential benefits of renal hypothermia for pro-
tection against ARF after TAAA repair.
The results of this study demonstrate several interesting
findings. First, contrary to our initial hypothesis, the use of
visceral cooling during renal ischemia did not alter the
subsequent incidence of ARF. Whether the use of local
hypothermia actually protected the kidneys from a cellular
or organ standpoint remains unknown, because our pri-
mary end point in this study was the simple clinical out-
come of ARF. Further studies analyzing biochemical and
molecular markers of renal injury are needed to answer this
question. While no obvious differences between the two
study groups (warm vs cold perfusion) exist, a prospective,
randomized study is needed to ensure no selection bias.
Second, 75% of ARF occurred within 1 postoperative day
and was balanced between the groups, suggesting that
onset of ARF is not influenced by method of visceral
perfusion. While late ARF does occur occasionally as a
consequence of sepsis or other late postoperative events,
most ARF occurred early in this study. Third, although
visceral cooling had no effect on the incidence of ARF after
TAAA repair, it significantly reduced hospital mortality in
this patient population. While the mechanism for this find-
ing is not completely understood, it is most likely explained
by our technique of visceral cooling, which includes perfu-
sion of the entire viscera, including the celiac, superior
mesenteric, and renal arteries, with cold blood during
reimplantation of the visceral segment of aorta. As a result
the liver and gut are also cooled, which likely reduces local
and systemic inflammation and organ injury induced by
mesenteric I/R.19 To address this question a study with
patients randomized to renal, mesenteric, or entire visceral
cooling will be performed in the future.
Acute renal failure after TAAA repair remains a signifi-
cant clinical problem. The mechanisms of ARF are likely
multifactorial and will require both local and systemic
measures against I/R-induced inflammation and injury.
While the use of visceral cooling during TAAA repair did
not alter the incidence of post-TAAA ARF in this study, it
significantly reduced hospital mortality in these patients.
Further clinical studies to investigate the role of therapeutic
visceral hypothermia for organ protection after TAAA re-
pair are needed.
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